Core Insights - The company Feihe has launched a new generation of products aimed at providing fresher and more suitable options for infants, emphasizing a comprehensive upgrade across the entire supply chain, breast milk formula, fresh nutrition, and feeding effectiveness [1][2] - Feihe's brand ambassador, Zhang Ziyi, highlighted the company's commitment over 63 years to cater to the nutritional needs of Chinese babies, continuously evolving to protect their health [1] - The rising health awareness among the public and the evolving parenting demands have led to a greater emphasis on "fresh" and "precise" nutrition for infants [1] Product Innovations - Feihe introduced multiple new products under the "New Generation More Suitable" line, including Qicui and Jicui, which replicate the nutritional ecosystem of breast milk and fresh ecology [2] - The company has established itself as a pioneer in clinical feeding research for infants, having conducted clinical trials since the launch of its flagship product, Xingfeifan, in 2010 [2] - Recent clinical evidence shows that Xingfeifan Zhuorui formula can achieve 100% similarity in growth and development effects compared to breast milk [2] Scientific Advancements - Feihe's Chief Scientist, Jiang Shilong, shared the latest clinical results, indicating a formula upgrade that includes HMOs, 100 times more probiotics, and GOS, along with the introduction of a proprietary "Brain Matrix" for brain nutrition [2] - The company announced three major authoritative certifications, including being the leader in Chinese breast milk research results, the number of patents in infant formula, and being the top brand for maternal source formula nutrition [2]

Core Viewpoint - The event highlighted the launch of "New Generation More Suitable" infant formula by Feihe, emphasizing its commitment to innovation and quality tailored for Chinese babies [1][3]. Group 1: Product Innovation - Feihe introduced the "Fresh Nutrition System," which focuses on fresh milk sources, raw materials, and processes to enhance the nutritional quality of its products [3][4]. - The company has developed a "Mother Source Bionic Formula" that closely mimics the nutritional profile of breast milk, including a significant upgrade in the Sn-2 DHA ratio to 52.5%, aligning closely with the average level found in breast milk [8]. Group 2: Research and Development - Feihe has been a pioneer in clinical feeding research for infants, with recent studies showing that its Star Flying Fan Zhuo Rui formula promotes infant growth and development similarly to breast milk [5][9]. - The company has participated in national research initiatives, including the "863 Program" and the "14th Five-Year Plan," to advance the understanding of Chinese breast milk [7][8]. Group 3: Industry Leadership - Feihe aims to lead the industry in establishing fresh nutrition standards and enhancing the overall quality of infant formula in China [3][4]. - The company emphasizes its responsibility as a leading brand to continue innovating and improving consumer services for the benefit of Chinese babies [8].

Core Insights - The infant formula market is experiencing intensified competition among leading brands, focusing on technological advancements rather than price wars as the initial growth from the baby boom in 2024 begins to wane [1][5] Industry Overview - The infant formula industry has seen a slight recovery in sales, with a 1.6% overall growth in the first eight months of 2025, primarily driven by a 13.5% increase in Stage 2 formula, while Stage 3 formula sales declined by 6.5% [2] - The birth rate in China reached 9.54 million in 2024, an increase of 520,000 from the previous year, marking a temporary rebound in the maternal and infant industry [2] - Despite the growth in sales figures for Stage 1 formula, this is attributed to improved market conditions rather than actual sales volume increases [4] Competitive Landscape - Leading brands are leveraging their research and development capabilities to differentiate their products, focusing on precision nutrition tailored to various age groups and regional dietary characteristics [5][6] - The competitive pressure on infant formula companies is expected to increase in the latter half of 2023 and into 2024, with larger brands' birth subsidy policies significantly impacting smaller brands, potentially reducing their sales by approximately 25% [5] - The number of registered formula series has decreased, but there is still room for increased market concentration, with 93 dairy companies having 426 formula series registered by the end of August 2025 [5]

Core Points - The stock price of Miaokelan has increased by 5.15% on October 15, reaching 27.38 CNY per share, with a trading volume of 346 million CNY and a turnover rate of 2.55%, resulting in a total market capitalization of 13.965 billion CNY [1] - Miaokelan's stock has risen for three consecutive days, with a cumulative increase of 7.07% during this period [1] Company Overview - Shanghai Miaokelan Food Technology Co., Ltd. was established on November 29, 1988, and listed on December 6, 1995 [1] - The company specializes in the research, development, production, and sales of dairy products, primarily focusing on cheese, which accounts for 83.20% of its main business revenue [1] - Other revenue sources include trade (8.94%), liquid milk (7.29%), and other products (0.57%) [1] Fund Holdings - According to data, one fund under the Fortune Fund has a significant holding in Miaokelan, specifically the Fortune SSE Index ETF Link A/B (100053), which held 400 shares as of the second quarter, ranking as the sixth largest holding [2] - The fund has generated a floating profit of approximately 536 CNY today and 688 CNY during the three-day increase [2] - The Fortune SSE Index ETF Link A/B was established on January 30, 2011, with a current scale of 274 million CNY and a year-to-date return of 16.29% [2]

Core Viewpoint - The article highlights the launch of Feihe's new generation of infant formula, emphasizing its alignment with the nutritional needs of Chinese babies through scientific innovation and a focus on "fresh" and "active" nutrition [2][6][12]. Group 1: Product Innovation - Feihe has introduced a "Fresh Nutrition System," which aims to enhance the quality and effectiveness of its products by focusing on fresh milk sources, active ingredients, and innovative processing techniques [5][8]. - The company has established a "2-hour ecological circle" for rapid low-temperature transportation of fresh milk to factories, ensuring the preservation of active nutrients [8]. - Feihe's new products, such as Qicui and Jicui, are designed to replicate the nutritional ecosystem of breast milk, thereby better stimulating the potential of babies [13][16]. Group 2: Scientific Research and Development - Feihe has been a pioneer in clinical feeding research for infants since 2010, with its flagship product, Xingfeifan, showing growth and development effects comparable to breast milk [15][18]. - The company has developed a "Chinese Mother Source Bionic Formula," closely matching the composition of Chinese breast milk, including a high proportion of Sn-2 DHA for better nutrient absorption [16][18]. - Feihe's commitment to research is underscored by its participation in national projects and the establishment of the largest maternal and child health cohort in China [16][18]. Group 3: Market Position and Consumer Trust - Feihe has achieved the highest sales in the infant formula market in China for six consecutive years and globally for four years, reflecting strong consumer trust [18]. - The company has over 85 million mothers relying on its "Star Mom Club" for scientific parenting guidance, showcasing its commitment to supporting parents [18][20]. - Feihe's brand ambassador, Zhang Ziyi, emphasizes the company's dedication to meeting the real needs of mothers and providing tangible support [20][23].

Core Viewpoint - The impact of the baby boom in the Year of the Dragon (2024) on the infant formula market is gradually diminishing, leading to intensified competition among leading dairy companies, which are now focusing more on technological advancements rather than price wars [1][3]. Market Trends - In the first eight months of 2025, the overall sales of infant formula in China showed a growth of 1.6%, primarily driven by a 13.5% increase in Stage 2 formula, while Stage 3 formula sales declined by 6.5% [4]. - The sales of Stage 1 formula increased by 9.4%, but this growth rate was lower than that of Stage 2 [5]. Industry Dynamics - The birth rate in China reached 9.54 million in 2024, an increase of 520,000 from the previous year, marking a temporary recovery in the maternal and infant industry [5]. - Despite the market recovery, there are concerns about the sustainability of growth, as the momentum for Stage 1 and overall infant formula sales is beginning to weaken [5]. Competitive Landscape - Leading infant formula brands are leveraging their research and technological advantages to squeeze out smaller brands, with companies like China Feihe announcing new product upgrades aimed at precise nutrition [1][7]. - The number of registered formula series has decreased, but there is still room for market concentration to increase, with 93 dairy companies having 426 formula series registered by the end of August 2025 [7]. Future Outlook - Analysts predict that the competition pressure on infant formula companies will intensify in the second half of the year and into 2026, as the effects of the birth boom wane [6][7]. - The focus on research and brand investment by leading companies is expected to attract new consumers, further accelerating market consolidation and reshuffling [7].

Core Insights - The impact of the baby boom in the Year of the Dragon (2024) on the infant formula market is gradually diminishing, leading to intensified competition among major brands focusing on technological advancements rather than price wars [1] - Major infant formula brands, including China Feihe, are launching upgraded products aimed at precise nutrition, reflecting a shift in strategy to maintain market share amid concerns over insufficient recovery momentum [1][2] - Despite a temporary increase in newborn population and sales growth in certain segments, the overall growth momentum for infant formula is weakening as the newborn bonus fades [2][4] Industry Trends - Data from Nielsen IQ indicates that from January to August 2025, the overall sales of infant formula in China grew by 1.6%, primarily driven by a 13.5% increase in Stage 2 formula, while Stage 3 saw a decline of 6.5% [2] - The newborn population in 2024 reached 9.54 million, an increase of 520,000 from the previous year, contributing to a brief recovery in the maternal and infant industry [2] - Market observations suggest a renewed decline in sales, with increasing brand differentiation and competition pressures, particularly for smaller brands facing challenges from larger competitors [4][5] Competitive Landscape - Major brands are leveraging their research and development capabilities to further squeeze the market share of smaller brands, with a focus on differentiated products tailored to specific age groups and dietary needs [5] - The number of registered infant formula brands has decreased, but there is still potential for increased market concentration, with 93 companies having 426 formula series registered by August 2025 [5] - Analysts predict that the competitive pressure on infant formula companies will intensify in the coming months, with the sustainability of recovery for leading brands remaining uncertain [4][5]

Core Viewpoint - The company Jule Co., Ltd. has faced significant challenges in its IPO journey, including the recent suspension of its application due to expired financial reports and the death of its founder, Tong Enwen, marking its fifth failed attempt to go public [1][3]. Company Developments - Jule Co., Ltd. has appointed Gao Zhaohui as the new chairman following the death of Tong Enwen, who was also the founder and had a strong desire to take the company public [2][3]. - Gao Zhaohui, who has extensive experience in various well-known companies, is seen as a potential successor capable of continuing the company's IPO efforts [2][3]. Financial Performance - Jule Co., Ltd. has shown revenue growth from 2020 to 2024, with revenues of 9.94 billion, 14.21 billion, 14.72 billion, 15.62 billion, and 16.41 billion respectively, and net profits of 1.3 billion, 1.58 billion, 1.72 billion, 1.96 billion, and 2.32 billion [4]. - The company's R&D expenditures from 2022 to 2024 were approximately 630 million, 474.1 million, and 514.9 million, representing a low percentage of revenue at 0.43%, 0.3%, and 0.31% respectively, which is below industry averages [4]. Innovation and Compliance Issues - The North Exchange has raised concerns regarding Jule Co., Ltd.'s innovation capabilities, particularly questioning the company's independent R&D capacity and the relevance of its patents to its main business [5][8]. - The company has been criticized for its low R&D investment and lack of innovative products, which are essential for meeting the North Exchange's requirements for listing [8]. IPO Challenges - Jule Co., Ltd. plans to raise 5.52 billion through its IPO, but this amount has decreased by 8.11 billion from previous applications, raising questions about the necessity and rationale of the fundraising projects [8]. - The company’s production capacity utilization rates from 2022 to 2024 were 85.29%, 78.44%, and 84.49%, indicating that the company has not fully optimized its production capabilities [8].

Core Viewpoint - Jule Co., Ltd. has suspended its IPO application on the Beijing Stock Exchange due to the expiration of its financial report, marking the fifth failed attempt to go public, compounded by the recent death of its founder, Tong Enwen [2][4]. Group 1: Company Leadership Changes - Following the death of Tong Enwen, Gao Zhaohui has been elected as the new chairman and legal representative of Jule Co., Ltd., also taking on key roles in various board committees [3]. - Gao Zhaohui, who is Tong Enwen's son-in-law, has extensive experience in notable companies and has been viewed as a successor capable of continuing the company's strategic vision [3][4]. Group 2: Financial Performance - Jule Co., Ltd. has shown consistent revenue growth from 2020 to 2024, with revenues increasing from 994 million to 1.641 billion yuan, and net profits rising from 130 million to 232 million yuan during the same period [5]. - Despite the growth in revenue, the company's R&D expenditure has been low, with amounts of approximately 6.3 million, 4.741 million, and 5.149 million yuan from 2022 to 2024, representing only 0.43%, 0.30%, and 0.31% of revenue, respectively [5]. Group 3: Innovation and R&D Challenges - The Beijing Stock Exchange has raised concerns regarding Jule Co., Ltd.'s innovation capabilities, questioning the company's independent R&D capacity and the relevance of its patents to its core business [6]. - The company has been criticized for its low R&D investment compared to industry standards, which may hinder its ability to meet the exchange's requirements for innovation [8]. Group 4: IPO Application and Market Conditions - Jule Co., Ltd. plans to raise 552 million yuan through its IPO, but this amount has decreased by 811 million yuan from its last application, raising questions about the necessity and rationale of the fundraising projects [8]. - The company aims to invest 278 million yuan in the expansion of its production base, which is projected to generate annual revenues of 935 million yuan upon completion, with an internal rate of return of 24.77% [8].

Core Viewpoint - The company Jule Co., Ltd. has faced significant challenges in its IPO journey, including the recent suspension of its application due to expired financial reports and the death of its founder, Tong Enwen, marking the fifth failed attempt to go public [1][3]. Group 1: Company Developments - Jule Co., Ltd. has announced the election of Gao Zhaohui as the new chairman following the death of Tong Enwen, who was also the founder [2]. - Gao Zhaohui, who is Tong Enwen's son-in-law, has extensive experience in various well-known companies and has been with Jule Co. since 2011 [2]. - The company has established four specialized committees within its board, with Gao Zhaohui holding key positions in three of them [2]. Group 2: Financial Performance - Jule Co., Ltd. has shown revenue growth from 9.94 billion in 2020 to 16.41 billion in 2024, with net profits increasing from 1.3 billion to 2.32 billion during the same period [4]. - The company's R&D expenses have been relatively low, with figures of approximately 630 million, 474.1 million, and 514.9 million from 2022 to 2024, representing only 0.43%, 0.30%, and 0.31% of revenue respectively [4]. Group 3: IPO Challenges - The North Exchange has raised concerns regarding Jule Co.'s compliance with innovation and financial metrics necessary for listing, particularly questioning the company's R&D capabilities and the relevance of its patents [5][6]. - The company plans to raise 5.52 billion through its IPO, but this amount has decreased by 8.11 billion from previous applications, raising doubts about the necessity and rationale of the fundraising projects [8]. - The proposed investment of 2.78 billion for the expansion of the Chengdu dairy production base is expected to generate annual revenue of 9.35 billion, with an internal rate of return of 24.77% [8].